Hereditary sensory and autonomic neuropathy type 4
Also known as CIP-anhidrosis syndrome, HSAN4, Hereditary Sensory and Autonomic Neuropathy Type IV, NTRK1 hereditary sensory and autonomic neuropathy+14 more
CIP-anhidrosis syndrome, HSAN4, Hereditary Sensory and Autonomic Neuropathy Type IV, NTRK1 hereditary sensory and autonomic neuropathy, congenital insensitivity to pain with anhidrosis, congenital insensitivity to pain-anhidrosis syndrome, hereditary sensory and autonomic neuropathy caused by mutation in NTRK1, hereditary sensory and autonomic neuropathy type IV, hereditary sensory neuropathy type IV, insensitivity to pain, congenital, with anhidrosis, CIPA, HSAN 4, HSAN IV, HSNAN4, familial dysautonomia, type 2, hereditary sensory and autonomic neuropathy 4, hereditary sensory neuropathy type 4, neuropathy, congenital sensory, with anhidrosis.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q2 2027.
- Q2 2027A Randomized Controlled Trial for Cervicothoracic Sympathetic Chain Block Against Sham Injection Evaluation for Post COVID Condition: the CeASE RCT
- Q2 2027Comparison of Suprainguinal Fascia Iliac Block With and Without Dexmedetomidine as an Adjunct to Ropivacaine for Postoperative Analgesia Following Hip Surgery: a Randomized, Double-blinded Study.
- Q4 2027A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty
- Q1 2028A Study on the Effect of GLP-1 Receptor Agonist (GLP-1RA) Intervention on Cardiac Autonomic Neuropathy in Patients With Type 2 Diabetes Mellitus
- Q3 2030Efficacy of Methylprednisolone for Pain Control After ACL Repair: A Randomized Controlled Trial
Clinical MilestonesView all 11Hide
- 2026-06-08A Randomized Controlled Trial for Cervicothoracic Sympathetic Chain Block Against Sham Injection Evaluation for Post COVID Condition: the CeASE RCTResults expected Q2 2027
- 2026-06-03A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip ArthroplastyResults expected Q4 2027
- 2026-04-30A Study on the Effect of GLP-1 Receptor Agonist (GLP-1RA) Intervention on Cardiac Autonomic Neuropathy in Patients With Type 2 Diabetes MellitusResults expected Q1 2028
- 2026-03-25Comparison of Suprainguinal Fascia Iliac Block With and Without Dexmedetomidine as an Adjunct to Ropivacaine for Postoperative Analgesia Following Hip Surgery: a Randomized, Double-blinded Study.Results expected Q2 2027
- 2025-10-24Efficacy of Methylprednisolone for Pain Control After ACL Repair: A Randomized Controlled TrialResults expected Q3 2030
- 2026-05-12Efficacy and Safety of Topical Lidocaine 23%/Tetracaine 7% Ointment Versus Placebo for Post-Hemorrhoidectomy Pain: A Double-Blind Randomized Controlled TrialCompleted
- 2025-10-29Effect of Virtual Reality Distraction in Reducing Patients' Pain and Anxiety During Peripheral Arterial Angioplasty: a Randomized Prospective StudyCompleted
- 2025-10-15Efficacy and Safety of Etoricoxib 90 mg + Diacerein 50 mg Capsule Compared to Meloxicam 15 mg + Diacerein 50 mg in Patients With Knee and/or Hip Osteoarthritis: A Phase III, Controlled, Randomized, Double-blind, Multicenter Clinical Trial.Completed
- 2027-12-01Guard3: An Open-label, Parallel-arm, Randomized, Controlled, Phase 2/Phase 3 Study Evaluating the Efficacy and Safety of Autologous HSC Gene Therapy, AVR-RD-02, Compared to ERT for Gaucher Disease Type 3 in Participants Aged 2 to 25Withdrawn
- 2026-02-26Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy: A Randomized Controlled TrialTerminated
- 2025-12-30A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic PainTerminated
- 2027-12-01ClinicalGuard3: An Open-label, Parallel-arm, Randomized, Controlled, Phase 2/Phase 3 Study Evaluating the Efficacy and Safety of Autologous HSC Gene Therapy, AVR-RD-02, Compared to ERT for Gaucher Disease Type 3 in Participants Aged 2 to 25Withdrawn
- 2026-06-08ClinicalA Randomized Controlled Trial for Cervicothoracic Sympathetic Chain Block Against Sham Injection Evaluation for Post COVID Condition: the CeASE RCTResults expected Q2 2027
- 2026-06-03ClinicalA Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip ArthroplastyResults expected Q4 2027
- 2026-05-12ClinicalEfficacy and Safety of Topical Lidocaine 23%/Tetracaine 7% Ointment Versus Placebo for Post-Hemorrhoidectomy Pain: A Double-Blind Randomized Controlled TrialCompleted
- 2026-04-30ClinicalA Study on the Effect of GLP-1 Receptor Agonist (GLP-1RA) Intervention on Cardiac Autonomic Neuropathy in Patients With Type 2 Diabetes MellitusResults expected Q1 2028
- 2026-03-25ClinicalComparison of Suprainguinal Fascia Iliac Block With and Without Dexmedetomidine as an Adjunct to Ropivacaine for Postoperative Analgesia Following Hip Surgery: a Randomized, Double-blinded Study.Results expected Q2 2027
- 2026-02-26ClinicalOpioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy: A Randomized Controlled TrialTerminated
- 2025-12-30ClinicalA Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic PainTerminated
- 2025-10-29ClinicalEffect of Virtual Reality Distraction in Reducing Patients' Pain and Anxiety During Peripheral Arterial Angioplasty: a Randomized Prospective StudyCompleted
- 2025-10-24ClinicalEfficacy of Methylprednisolone for Pain Control After ACL Repair: A Randomized Controlled TrialResults expected Q3 2030
Clinical trials
The current development programme across all trial phases.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
CIP-anhidrosis syndrome, HSAN4, Hereditary Sensory and Autonomic Neuropathy Type IV, NTRK1 hereditary sensory and autonomic neuropathy, congenital insensitivity to pain with anhidrosis, congenital insensitivity to pain-anhidrosis syndrome, hereditary sensory and autonomic neuropathy caused by mutation in NTRK1, hereditary sensory and autonomic neuropathy type IV, hereditary sensory neuropathy type IV, insensitivity to pain, congenital, with anhidrosis, CIPA, HSAN 4, HSAN IV, HSNAN4, familial dysautonomia, type 2, hereditary sensory and autonomic neuropathy 4, hereditary sensory neuropathy type 4, neuropathy, congenital sensory, with anhidrosis
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.